CP-x Synthetic Cannabinoids Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 94 studies associated with CP-x Synthetic Cannabinoids.
Here is a small sampling of CP-x Synthetic Cannabinoids studies by title:
- Synthetic cannabinoid CP-55,940 induces apoptosis in a human skeletal muscle model via regulation of CB1 receptors and L-type Ca2+ channels
- Involvement of spinal G-protein inwardly rectifying potassium (GIRK) channels in the enhanced antinociceptive effects of the activation of both μ-opioid and cannabinoid CB1 receptors
- Age-dependent hormesis-like effects of the synthetic cannabinoid CP55940 in C57BL/6 mice
- Cannabinoid-profiled agents improve cell survival via reduction of oxidative stress and inflammation, and Nrf2 activation in a toxic model combining hyperglycemia+Aβ 1-42 peptide in rat hippocampal neurons
- The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species
Components of the CP-x Synthetic Cannabinoids Research Dashboard
- Top medical conditions associated with CP-x Synthetic Cannabinoids
- Proven effects in clinical trials for CP-x Synthetic Cannabinoids
- Receptors associated with CP-x Synthetic Cannabinoids
- Individual study details for CP-x Synthetic Cannabinoids
Ready to become a subscriber? Go to our PRICING page.
Page Quick Links
Select New Cannabinoid
Overview - CP-x Synthetic Cannabinoids
Description of CP-x Synthetic Cannabinoids
The CP- class of synthetic cannabinoids are named after the company Carl Pfizer where they were first synthesized. CP-55,940 was discovered in 1974 and is one of the most studied member of this class. It binds to the same classical endocannabinoid receptor sites i.e., CB1 and CB2 as THC albeit with stronger efficacies (see receptor binding).
Here we focus on CP-55,940
Other members of the CP-x class include: • CP-47,497 • CP-50,556-1 (aka Levonantradol) • CP-55,244 • CP-945,598 (aka Otenabant) • Plus others
Other Names:
CP Family of Synthetic CannabinoidsCP-55,940 syn.: CP55,940; CP-55940 plus numerous supplier-based synonyms.
IUPAC Name: 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
Molecular Formula: C24H40O3
Source–PubChem
CP-x Synthetic Cannabinoids Properties and Effects
Only Members can view Properties and Effects information. See DEMO page.
CP-x Synthetic Cannabinoids Receptor Binding
Only Members can view Receptor Binding information. See DEMO page.
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
